HC Wainwright Forecasts Biomea Fusion Q1 Earnings

Biomea Fusion, Inc. (NASDAQ:BMEA) – Stock analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Biomea Fusion in a research report issued on Tuesday, April 1st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.85) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.03) EPS and Q4 2025 earnings at ($1.11) EPS.

A number of other equities research analysts have also issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price objective on shares of Biomea Fusion in a report on Wednesday, March 19th. Barclays cut their target price on shares of Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Oppenheimer set a $10.00 price target on shares of Biomea Fusion in a research note on Monday, March 24th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $23.91.

Biomea Fusion Trading Up 8.5 %

NASDAQ:BMEA opened at $2.16 on Wednesday. The stock has a 50-day moving average price of $3.19 and a 200 day moving average price of $5.89. The stock has a market capitalization of $78.28 million, a P/E ratio of -0.54 and a beta of -0.26. Biomea Fusion has a 12-month low of $1.87 and a 12-month high of $14.43.

Biomea Fusion (NASDAQ:BMEA) last released its earnings results on Monday, March 31st. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.19.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BMEA. Bayesian Capital Management LP bought a new stake in shares of Biomea Fusion in the 4th quarter valued at approximately $42,000. The Manufacturers Life Insurance Company bought a new stake in Biomea Fusion in the third quarter worth $111,000. Wells Fargo & Company MN boosted its stake in Biomea Fusion by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 12,914 shares of the company’s stock worth $50,000 after buying an additional 4,399 shares during the period. Intech Investment Management LLC bought a new position in Biomea Fusion during the fourth quarter valued at $54,000. Finally, Maia Wealth LLC purchased a new stake in shares of Biomea Fusion in the fourth quarter valued at $62,000. Hedge funds and other institutional investors own 96.72% of the company’s stock.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.